Abstract:Background and objectives: Gastrointestinal dysmotility is common in pediatric short-bowel syndrome, leading to prolonged parenteral nutrition dependence. There is limited literature regarding the safety and efficacy of cisapride for this indication. The aim of the study was to describe the safety and efficacy of cisapride for enteral intolerance in pediatric short-bowel syndrome. Methods: Open-labeled pilot study in a limited access program for cisapride. Indications were short-bowel syndrome with underlying dysmotility and difficulty advancing enteral feeds despite standard therapies and without evidence of anatomic obstruction. Patients received cisapride 0.1 to 0.2 mg/kg per dose for 3 to 4 doses per day. We collected electrocardiogram, nutrition, and anthropometric data prospectively at study visits. Results: Ten patients with mean (SD) age of 30.3 (30.5) months were enrolled in our multidisciplinary pediatric intestinal rehabilitation program. Median (interquartile range [IQR]) duration of follow-up was 8.7 (3.1-14.3) months. Median (IQR) residual bowel length was 102 (85-130) cm. Median (IQR) citrulline level was 14.5 (10.5-31.3) μmol/L. Diagnoses included isolated gastroschisis (n = 3), gastroschisis with intestinal atresia (n = 4), necrotizing enterocolitis (n = 2), and long-segment Hirschsprung disease (n = 1). Six subjects had at least 1 prior bowel-lengthening procedure. Median (IQR) change in percentage enteral energy intake was 19.9% (15.4%-29.8%) during follow-up (P = 0.01). Seven patients improved in enteral tolerance during treatment and 2 were weaned completely from parenteral nutrition. Complications during therapy were prolonged corrected QT interval (n = 2), gastrointestinal bleeding (n = 2), D-lactic acidosis (n = 1), and death due to presumed sepsis (n = 1). Longitudinal analysis (general estimating equation model) showed a strong positive association between cisapride duration and improved enteral tolerance. Mean percentage of enteral intake increased by 2.9% for every month of cisapride treatment (P < 0.0001). Conclusions: Cisapride is a potentially useful therapy in patients with pediatric short-bowel syndrome with gastrointestinal dysmotility. We observed modest improvement in feeding tolerance where prior treatments failed; however, patients treated with cisapride require careful cardiac monitoring because corrected QT prolongation occurred in 20% of our cohort.

Anorectal manometric abnormalities and effect of cisapride in patients with chronic idiopathic constipation

Sa1383 Efficacy of Multidisciplinary Approach for the Management of Severe Constipation: A 4-Year Experience

Efficacy and Safety of Linaclotide in Patients with Irritable Bowel Syndrome with Constipation: Chinese Sub-Cohort Analysis of a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial.

Efficacy and Safety of Lubiprostone for the Treatment of Functional Constipation in Chinese Adult Patients: A Multicenter, Randomized, Double‐blind, Placebo‐controlled Trial

The Effect of Cisapride on Colonic Transit Time in Patients with Chronic Functional Constipation

Cisapride Versus Maren Pill for Functional Constipation: A Meta-Analysis

The therapeutic efficacy evaluation of modified Bresler in the treatment of obstructed defecation syndrome associated with rectocele and rectal mucosal prolapse

A Clinical Study on Colonic Motility and Anorectal Manometry in Irritable Bowel Syndrome with Constipation and Functional Constipation

Efficacy and safety of cinitapride in the treatment of mild to moderate postprandial distress syndrome-predominant functional dyspepsia.

Cisapride improves enteral tolerance in pediatric short-bowel syndrome with dysmotility

Efficacy and Safety of Calcium Polycarbophil in the Treatment of Constipation-Predominant Irritable Bowel Syndrome

[Effect of Zhizhuwan on Gastrointestinal Peptide Concentrations in Plasma of Diabetic Gastroenteropathy with Constipation Patients].

Effect of cisapride on intestinal bacterial and endotoxin translocation in cirrhosis

Influence of Demographic Factors on Clinical Outcomes in Adults With Chronic Idiopathic Constipation Treated With Plecanatide

Prucalopride in the Treatment of Chinese Patients with Chronic Constipation: a Randomised, Double-Blind,placebo-controlled Study

Examining linaclotide for the treatment of chronic idiopathic constipation

Influence of Cisapride on Gastric Emptying of Solids and Liquids Monitored by 13C Breath Tests.

High-resolution manometry reveals different effect of polyethylene glycol, bisacodyl, and prucalopride on colonic motility in healthy subjects: An acute, open label, randomized, crossover, reader-blinded study with potential clinical implications

Chronic constipation-associated symptoms in Asians and non-Asians, and effects of 12-week prucalopride treatment: A pooled analysis of 4 randomized, placebo-controlled trials.

Effect of Prucalopride in the Treatment of Chronic Constipation in Asian and Non-Asian Women: A Pooled Analysis of 4 Randomized, Placebo-Controlled Studies

[Effect of Changji' an Oral Liquid on Activated Signal Alterative Intensity in Algesthesia Domain in Patients with Diarrhea Type Irritable Bowel Syndrome Due to Gan-Pi Disharmony].